Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26

EQL Pharma AB (publ) will publish its interim report for the third quarter 2025/26 on Tuesday, February 3, 2026, and will host a video presentation for shareholders on February 4 at 10:00 CET where CEO Axel Schörling will present and take questions. The Lund-based generics specialist, listed on Nasdaq Stockholm, currently markets 46 niche generics in the Nordic region and states it has a significant pipeline of additional niche generics planned for launch in 2026 and beyond. The notice contains no financial figures or guidance.

Analysis

Market structure: EQL Pharma (Nasdaq Stockholm: EQL) is a beneficiary if its 2026 niche generic launches convert to hospital formularies — winners include EQL, its contract manufacturing partners (EU/Asia CMOs) and procurement-driven hospital buyers; losers are incumbent originator brands for those niche drugs and EU-based higher-cost generic entrants. Niche positioning implies limited initial price erosion, supporting gross margins near current levels for 6–18 months, but long-term pricing power depends on tender dynamics and number of entrants. Cross-asset impact is muted; expect idiosyncratic equity moves (±10–40%), minimal macro bond/commodity effect, and modest SEK/EUR sensitivity as revenues concentrate in Nordics/EU.

Risk assessment: Key tail risks are regulatory/GMP failures at CMO partners, IP litigation from originators, and sudden tender-driven price collapse; any single CMO failure could cut supply for months and depress EPS by >20% in near term. Immediate horizon (days): volatility around Feb 3–4 interim release; short-term (weeks/months): tender results and first 2026 launches; long-term (quarters/years): competitor entry and reimbursement changes. Hidden dependency: concentrated CMO relationships and hospital tender windows; catalysts to watch are Feb interim, Q4 sales detail, and specific tender awards over next 60–120 days.

Trade implications: For active accounts, a small directional exposure captures asymmetric upside from successful launches while limiting idiosyncratic downside: consider a 2–3% long equity position or 1–2% notional buy of 6–10 week ATM calls around Feb 3–4, with a 20% stop-loss on equity and preset take-profit at +30–40% within 3–12 months. Pair idea: long EQL (2%) vs short TEVA (NYSE: TEVA, 1%) for 3–6 months to isolate niche-win vs broad generic softness. If implied volatility is low, prefer call spreads to cap premium outlay; buy protective puts (5–10% notional) if holding through results.

Contrarian angles: Consensus likely underweights revenue upside from several niche launches in 2026 because the market generalizes all generics as commoditized; that misses tender-driven volume spikes where first-mover niche suppliers capture 60–80% share for 6–12 months. Conversely, consensus may underprice regulatory/CMO concentration risk — a single GMP failure could cause >30% drawdown. Historical parallel: small-cap niche generics that won hospital tenders saw rapid revenue inflections then later margin compression as entrants arrived; trade with clear exit triggers tied to tender and GMP signals.

Key Decisions for Investors

• Establish a 2–3% long position in EQL Pharma (Nasdaq Stockholm: EQL) ahead of the Feb 3 interim release and Feb 4 presentation; set hard stop-loss at -20% and target +30–40% within 3–12 months if pipeline launch metrics (two+ product launches or ≥10% sequential revenue growth) are confirmed.
• If preferring limited downside, buy 6–10 week ATM call options on EQL sized to 1–2% of portfolio notional expiring mid-March 2026; if IV is low, implement call spreads (buy ATM, sell 20% OTM) and sell into any >30% post-release pop.
• Execute a relative-value pair: long EQL 2% vs short TEVA (NYSE: TEVA) 1% for 3–6 months to express niche-outperformance; close both legs if EQL misses tender wins or if TEVA outperforms by >15%.
• Monitor regulatory/tender events closely: if any CMO GMP failure, failed Swedish/EMA inspection, or loss of a named tender representing an estimated >5% of revenue is announced within 60 days, reduce EQL long to zero and cover option positions immediately.